Home LiteratureArticle Details
PMID: 18079360 Published · ppublish English Case Reports Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study.

Neuro-oncology ·Vol. 10 ·No. 1 ·2008-02-00 ·Pages 98-103

Heimberger AB, Sun W, Hussain SF, Dey M, Crutcher L, Aldape K, Gilbert M, Hassenbusch SJ, Sawaya R, Schmittling B, Archer GE, Mitchell DA, Bigner DD, Sampson JH

Abstract

Cytotoxic chemotherapy that induces lymphopenia is predicted to ablate the benefits of active antitumor immunization. Temozolomide is an effective chemotherapeutic agent for patients with glioblastoma multiforme, but it induces significant lymphopenia. Although there is monthly fluctuation of the white blood cell count, specifically the CD4 and CD8 counts, there was no cumulative decline in the patient described in this case report. Depriving patients of this agent, in order to treat with immunotherapy, is controversial. Despite conventional dogma, we demonstrated that chemotherapy and immunotherapy can be delivered concurrently without negating the effects of immunotherapy. In fact, the temozolomide-induced lymphopenia may prove to be synergistic with a peptide vaccine secondary to inhibition of regulatory T cells or their delayed recovery.

MeSH Terms
Antineoplastic Agents, Alkylating Brain Neoplasms/immunology,therapy Cancer Vaccines/immunology,therapeutic use Combined Modality Therapy Dacarbazine/analogs & derivatives ErbB Receptors/immunology,metabolism Flow Cytometry Glioblastoma/immunology,therapy Humans Immunotherapy/methods Male Middle Aged Radiotherapy T-Lymphocyte Subsets/immunology T-Lymphocytes/immunology Temozolomide Vaccines, Subunit
Chemicals
Antineoplastic Agents, Alkylating Cancer Vaccines Vaccines, Subunit Dacarbazine ErbB Receptors Temozolomide
Authors & Affiliations
14 authors, click to expand affiliations / ORCID
Heimberger Amy B
Department of Neurosurgery, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030-4009, USA. [email protected]
Sun Wei
Hussain S Farzana
Dey Mahua
Crutcher Lamonne
Aldape Ken
Gilbert Mark
Hassenbusch Samuel J
Sawaya Raymond
Schmittling Bob
Archer Gary E
Mitchell Duane A
Bigner Darell D
Sampson John H
References (25)
25 references, click to expand
  1. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.
    Cancer Res. 2006 Mar 15;66(6):3294-302 PMID: 16540683
  2. Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo.
    Cancer Res. 1991 Apr 15;51(8):2164-72 PMID: 2009534
  3. MGMT gene silencing and benefit from temozolomide in glioblastoma.
    N Engl J Med. 2005 Mar 10;352(10):997-1003 PMID: 15758010
  4. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment.
    Clin Cancer Res. 2005 Aug 1;11(15):5515-25 PMID: 16061868
  5. Flow cytometric measurement of intracellular cytokines detects immune responses in MUC1 immunotherapy.
    Clin Cancer Res. 2000 Mar;6(3):829-37 PMID: 10741704
  6. Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells.
    Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4294-305 PMID: 16857805
  7. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors.
    Clin Cancer Res. 2003 Sep 15;9(11):4247-54 PMID: 14519652
  8. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII.
    Cancer Res. 1997 Sep 15;57(18):4130-40 PMID: 9307304
  9. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine.
    Cancer Res. 1994 Apr 1;54(7):1766-71 PMID: 7511051
  10. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications.
    J Clin Oncol. 2004 Feb 15;22(4):610-6 PMID: 14726505
  11. Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts.
    Cancer Res. 1988 Apr 15;48(8):2231-8 PMID: 3258189
  12. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells.
    J Exp Med. 2005 Oct 3;202(7):907-12 PMID: 16203864
  13. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.
    J Exp Med. 1982 Apr 1;155(4):1063-74 PMID: 6460831
  14. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.
    Science. 2002 Oct 25;298(5594):850-4 PMID: 12242449
  15. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.
    J Clin Oncol. 2005 Apr 1;23(10):2346-57 PMID: 15800326
  16. Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance.
    J Neuropathol Exp Neurol. 2004 Jul;63(7):700-7 PMID: 15290895
  17. Fas/CD95-mediated apoptosis in human glioblastoma cells: a target for sensitisation to topoisomerase I inhibitors.
    Biochem Pharmacol. 2002 Mar 1;63(5):881-7 PMID: 11911840
  18. Effect of the combined treatment with 5-fluorouracil, gamma-interferon or folinic acid on carcinoembryonic antigen expression in colon cancer cells.
    Clin Cancer Res. 1998 Oct;4(10):2473-81 PMID: 9796980
  19. Specificity of adoptive chemoimmunotherapy of established syngeneic tumors.
    J Immunol. 1980 Aug;125(2):711-4 PMID: 6156213
  20. Use of overlapping peptide mixtures as antigens for cytokine flow cytometry.
    J Immunol Methods. 2001 Sep 1;255(1-2):27-40 PMID: 11470284
  21. Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma.
    Neurosurgery. 2002 Jan;50(1):158-64; discussion 164-6 PMID: 11844246
  22. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
    N Engl J Med. 2005 Mar 10;352(10):987-96 PMID: 15758009
  23. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.
    J Immunol. 2005 Mar 1;174(5):2591-601 PMID: 15728465
  24. T cells compete for access to antigen-bearing antigen-presenting cells.
    J Exp Med. 2000 Oct 16;192(8):1105-13 PMID: 11034600
  25. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients.
    Clin Cancer Res. 2005 Feb 15;11(4):1462-6 PMID: 15746047
Article Info
Journal
Neuro-oncology
Abbr.
Neuro Oncol
ISSN
1522-8517
DOI
10.1215/15228517-2007-046
Email
[email protected]
Published
2008-02-00
Epub
2007-00-13
Pages
98-103
Language
English
Region
England
NLM ID
100887420
PMCID
PMC2600844
Subset
IM
Grants
NCI NIH HHS · P50 CA108786 · United States
NCI NIH HHS · 1P50 CA108786 · United States
NCI NIH HHS · R01 CA09722 · United States
External Links
PubMed source DOI: 10.1215/15228517-2007-046 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2